Volume | 32,381 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
GRI Bio Inc | GRI | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.289899 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
89 | 32,381 | - | 0.2701 - 47.95 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
07:29:09 | formt | 2,486 | $ 0.30 | USD |
GRI Bio Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 1.13M | - | - | - | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
GRI Bio News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GRI Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.325 | 0.37 | 0.2701 | 0.2985551 | 758,641 | -0.025 | -7.69% |
1 Month | 0.419 | 0.4798 | 0.2701 | 0.3739412 | 682,134 | -0.119 | -28.40% |
3 Months | 0.808 | 0.846 | 0.2701 | 0.4455396 | 320,096 | -0.508 | -62.87% |
6 Months | 4.4471 | 5.00 | 0.2701 | 1.44 | 557,510 | -4.15 | -93.25% |
1 Year | 42.00 | 47.95 | 0.2701 | 3.17 | 389,335 | -41.70 | -99.29% |
3 Years | 92.40 | 93.31 | 0.2701 | 3.73 | 354,497 | -92.10 | -99.68% |
5 Years | 92.40 | 93.31 | 0.2701 | 3.73 | 354,497 | -92.10 | -99.68% |
GRI Bio Description
GRI Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a pipeline of Natural Killer T (NKT) modulating therapies for the treatment of inflammatory, fibrotic and autoimmune diseases. The Company's lead program, GRI-0621 is a small molecule RAR-beta dual agonist that inhibits the activity of human Type I, or invariant, NKT (iNKT) cells, which is being developed for the treatment of Idiopathic pulmonary fibrosis (IPF). GRI-0621 is a once-daily oral capsule for several fibrotic indications. The Company¿s second asset GRI-0803, is a novel activator of human Type 2 NKT cells in development for the treatment of autoimmune disorders, with an initial focus on systemic lupus erythematosus. Additionally, the Company has a library of 500+ proprietary compounds targeting a number of high value indications with unmet need. |